1. Home
  2. TIL vs CCRD Comparison

TIL vs CCRD Comparison

Compare TIL & CCRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TIL
  • CCRD
  • Stock Information
  • Founded
  • TIL 2018
  • CCRD 1973
  • Country
  • TIL United States
  • CCRD United States
  • Employees
  • TIL N/A
  • CCRD N/A
  • Industry
  • TIL Biotechnology: Pharmaceutical Preparations
  • CCRD
  • Sector
  • TIL Health Care
  • CCRD
  • Exchange
  • TIL Nasdaq
  • CCRD Nasdaq
  • Market Cap
  • TIL 171.7M
  • CCRD 157.9M
  • IPO Year
  • TIL 2021
  • CCRD N/A
  • Fundamental
  • Price
  • TIL $14.48
  • CCRD $19.07
  • Analyst Decision
  • TIL Buy
  • CCRD Hold
  • Analyst Count
  • TIL 5
  • CCRD 1
  • Target Price
  • TIL $114.00
  • CCRD $21.00
  • AVG Volume (30 Days)
  • TIL 178.2K
  • CCRD 17.4K
  • Earning Date
  • TIL 05-13-2025
  • CCRD 05-08-2025
  • Dividend Yield
  • TIL N/A
  • CCRD N/A
  • EPS Growth
  • TIL N/A
  • CCRD 67.50
  • EPS
  • TIL N/A
  • CCRD 0.67
  • Revenue
  • TIL N/A
  • CCRD $57,399,000.00
  • Revenue This Year
  • TIL N/A
  • CCRD $9.82
  • Revenue Next Year
  • TIL N/A
  • CCRD N/A
  • P/E Ratio
  • TIL N/A
  • CCRD $28.40
  • Revenue Growth
  • TIL N/A
  • CCRD 2.49
  • 52 Week Low
  • TIL $9.62
  • CCRD $11.54
  • 52 Week High
  • TIL $92.00
  • CCRD $24.97
  • Technical
  • Relative Strength Index (RSI)
  • TIL 46.45
  • CCRD 47.19
  • Support Level
  • TIL $10.80
  • CCRD $18.95
  • Resistance Level
  • TIL $13.52
  • CCRD $20.30
  • Average True Range (ATR)
  • TIL 2.23
  • CCRD 0.97
  • MACD
  • TIL -0.17
  • CCRD 0.09
  • Stochastic Oscillator
  • TIL 27.06
  • CCRD 28.71

About TIL Instil Bio Inc.

Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize FRα, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.

About CCRD CoreCard Corporation

CoreCard Corp is engaged in the business of providing technology solutions and processing services to the financial technology and services market. It designs, develops and markets a comprehensive suite of software solutions to program managers, accounts receivable businesses, financial institutions, retailers and processors to manage their credit and debit cards, prepaid cards, private label cards, fleet cards, buy now pay later programs, loyalty programs and accounts receivable and loan transactions. The CoreCard software platform and modules include CoreENGINE, CoreISSUE, CoreFRAUD, CoreCOLLECT, CoreAPP, CoreMONEY and CoreACQUIRE. Its customers are located in the U.S, European Union and the Middle East of which key revenue is derived from the U.S.

Share on Social Networks: